[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339828-105":59,"doc-detail-339828-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-safety-and-efficacy-of-binimetinib-for-lung-cancer-a-systematic-review","The safety and efficacy of binimetinib for lung cancer: a systematic review","","Lung cancer remains a major global health burden, especially for non-small cell lung cancer (NSCLC) where late diagnosis and drug resistance limit treatment options. The mitogen-activated protein kinase (MAPK) pathway is implicated in NSCLC, supporting MEK inhibition as a potential therapeutic approach. This systematic review evaluated binimetinib’s safety and efficacy for lung cancer by pooling clinical trial evidence to characterize adverse events and clinical outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-safety-and-efficacy-of-binimetinib-for-lung-cancer-a-systematic-review/339828/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-safety-and-efficacy-of-binimetinib-for-lung-cancer-a-systematic-review/339828.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why was binimetinib investigated for lung cancer treatment?","Question",{"text":112,"@type":113},"Because dysregulation of the MAPK pathway and MEK involvement in NSCLC suggests that MEK inhibitors may improve outcomes. Prior results in other cancers motivated evaluation in lung cancer specifically.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were studies selected for this systematic review?",{"text":117,"@type":113},"The review searched PubMed, Scopus, Web of Science, and Google Scholar up to September 2023 and included clinical trials assessing binimetinib’s efficacy or safety for lung cancer. Trials were excluded when participants had unrelated conditions, evaluated other treatments, or used different study designs.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety and efficacy outcomes were most reported?",{"text":121,"@type":113},"Most patients experienced all-cause adverse events, with diarrhea, fatigue, and nausea commonly reported. Efficacy metrics included an objective response rate up to 75% and median progression-free survival up to 9.3 months, while treatment-related serious adverse events occurred in more than half of patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339828,1790095685,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Zahmatyar etal. BMC Pulmonary Medicine (2024) 24:379  \n[https://doi.org/10.1186/s12890-024-03178-4](https://doi.org/10.1186/s12890-024-03178-4)  \nBMC Pulmonary Medicine  \nSYSTEMATIC REVIEW Open Access  \nThe safety and efficacy of binimetinib for lung cancer: a systematic review  \nMahdi Zahmatyar 1,2, Ladan Kharaz3, Negin Abiri Jahromi4†, Ali Jahanian3†, Pourya Shokri3† and Seyed Aria Nejadghaderi5,6*  \nAbstract  \nBackground Lung cancer, accounting for a significant proportion of global cancer cases and deaths, poses a considerable health burden. Non-small cell lung cancer (NSCLC) patients have a poor prognosis and limited treatment options due to late-stage diagnosis and drug resistance. Dysregulated of the mitogen-activated protein kinase (MAPK) pathway, which is implicated in NSCLC pathogenesis, underscores the potential of MEK inhibitors such as binimetinib. Despite promising results in other cancers, comprehensive studies evaluating the safety and efficacy of binimetinibin lung cancer are lacking. This systematic review aimed to investigate the safety and efficacy of binimetinib for lung cancer treatment.  \nMethods We searched PubMed, Scopus, Web of Science, and Google Scholar until September 2023. Clinical trials evaluating the efficacy or safety of binimetinib for lung cancer treatment were included. Studies were excluded if they included individuals with conditions unrelated to lung cancer, investigated other treatments, or had different types of designs. The quality assessment was conducted utilizing the National Institutes of Health tool.  \nResults Seven studies with 228 participants overall were included. Four had good quality judgments, and three had fair quality judgments. The majority of patients experienced all-cause adverse events, with diarrhea, fatigue, and nausea being the most commonly reported adverse events of any grade. The objective response rate (ORR) was up to 75%, and the median progression-free survival (PFS) was up to 9.3 months. The disease control rate after 24 weeks varied from 41% to 64% . Overall survival (OS) ranged between 3.0 and 18.8 months. Notably, treatment-related adverse events were observed in more than 50% of patients, including serious adverse events such as colitis, febrile neutropenia, and pulmonary infection. Some adverse events led to dose limitation and drug discontinuation in five studies. Additionally, five studies reported cases of death, mostly due to disease progression. The median duration of treatment ranged from 14.8 weeks to 8.4 months. The most common dosage of binimetinib was 30 mg or 45 mg twice daily, sometimes used in combination with other agents like encorafenib or hydroxychloroquine.  \nConclusions Only a few studies have shown binimetinib to be effective, in terms of improving OS, PFS, and  \nORR, while most of the studies found nonsignificant efficacy with increased toxicity for binimetinib compared  \n†Negin Abiri Jahromi, Ali Jahanian and Pourya Shokri contributed equally to this work.  \n*Correspondence:  \nSeyed Aria Nejadghaderi  \n[ariaghaderi@sbmu.ac.ir](ariaghaderi@sbmu.ac.ir); [ariang20@gmail.com](ariang20@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyrigh","cbCaihiq0Aq8Ded1","https://ap.wps.com/l/cbCaihiq0Aq8Ded1","pdf",2159643,13,"English","# Abstract\n# Methods\n# Results\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"Why was binimetinib investigated for lung cancer treatment?\",\"answer\":\"Because dysregulation of the MAPK pathway and MEK involvement in NSCLC suggests that MEK inhibitors may improve outcomes. Prior results in other cancers motivated evaluation in lung cancer specifically.\"},{\"question\":\"How were studies selected for this systematic review?\",\"answer\":\"The review searched PubMed, Scopus, Web of Science, and Google Scholar up to September 2023 and included clinical trials assessing binimetinib’s efficacy or safety for lung cancer. Trials were excluded when participants had unrelated conditions, evaluated other treatments, or used different study designs.\"},{\"question\":\"What safety and efficacy outcomes were most reported?\",\"answer\":\"Most patients experienced all-cause adverse events, with diarrhea, fatigue, and nausea commonly reported. Efficacy metrics included an objective response rate up to 75% and median progression-free survival up to 9.3 months, while treatment-related serious adverse events occurred in more than half of patients.\"}]","The safety and efficacy of binimetinib for lung cancer: a systematic review | PDF",1790032483,33]